JP Morgan Chase
ZVSA

JP Morgan Chase’s ZyVersa Therapeutics ZVSA Stock Holding History

JP Morgan Chase’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$2 – 7778
2024
Q3 		$2 Hold
1
– – ﹤0.01% 7364
2024
Q2 		$4 Buy
+1
New +$5 ﹤0.01% 7257
2024
Q1 		– Hold
0
– – – 7344

Other funds holding ZVSA

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's ZVSA Position: Q4 2024 in Review

JP Morgan Chase sold out of ZyVersa Therapeutics (ZVSA) in Q4 2024, closing a stake of 1 share — an estimated $2 sold.

JP Morgan Chase first reported a position in ZVSA in Q2 2024 and held it in 2 quarters. The position peaked at $4 in Q2 2024. 8 funds tracked by Wall St. Rank hold ZVSA as of Q4 2024.

  • JP Morgan Chase reported no remaining ZyVersa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 1 ZyVersa Therapeutics share in Q4 2024, an estimated $2.
  • JP Morgan Chase first reported a position in ZyVersa Therapeutics in Q2 2024 and held it in 2 quarters.
  • JP Morgan Chase's ZyVersa Therapeutics position peaked at $4 in Q2 2024.
  • 8 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.